CCL19 and neoplasm: Additionally, these researchers reported that the administration of CCL19-IL-7 CAR-Ts into mouse models also led to an increase in the number of other tumor-site trafficking immune cells alongside suppressing the expression of exhaustion markers (such as PD-1) on the endogenous T lymphocytes (155).